Lv1
52 积分 2024-08-09 加入
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies
2天前
已完结
Heart–liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework
1个月前
已完结
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
2个月前
已完结
The global cardiovascular–liver–metabolic syndemic: epidemiology, trends and challenges
2个月前
已完结
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
5个月前
已完结
mRNA medicine for cardiovascular disease
6个月前
已完结
Early steps in reverse cholesterol transport cholesteryl ester hydrolase and other hydrolases
8个月前
已完结
Controlling the biodistribution and clearance of nanomedicines
8个月前
已完结
IRF5 siRNA Nanoimmunotherapy: Restoring Macrophage Efferocytosis in Atherosclerosis
9个月前
已完结
IRF5 siRNA Nanoimmunotherapy: Restoring Macrophage Efferocytosis in Atherosclerosis
10个月前
已完结